Industries > Pharma > Anti-Idiopathic Pulmonary Fibrosis Drugs Market Report 2021-2031

Anti-Idiopathic Pulmonary Fibrosis Drugs Market Report 2021-2031

Antifibrotics, Tyrosine Kinase Inhibitors, Anti-inflammatory Drugs, Immunosuppressants, Other MoA, Innovator Drugs plus Leading Anti-Idiopathic Pulmonary Fibrosis Drugs companies analysis

PAGES: 171
PRODUCT CODE: PHA0788
SUBMARKET: Therapeutic Drugs

DOWNLOAD FREE SAMPLE
Clear
WOOCS 2.2.1
SKU: PHA0788 Categories: , Tag:

The global anti-idiopathic pulmonary fibrosis drugs market is expected to grow at a CAGR of xyz% in the first half of the forecast period. In 2018, the anti-fibrotics held the largest market share (xyz%) followed by the tyrosine kinase inhibitors.

How this report will benefit you
Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 170+ page report you will receive over 70 tables and figures– all unavailable elsewhere.

The 171-page report provides clear detailed insight into the global anti-idiopathic pulmonary fibrosis drugs market. Discover the key drivers and challenges affecting the market.

To access the data contained in this document please email contactus@visiongain.com

By ordering and reading our brand-new report today you stay better informed and ready to act.

Report Scope

• Global Anti-Idiopathic Pulmonary Fibrosis Drugs market forecasts to 2021

• This report also breaks down the revenue forecast for the global anti-idiopathic pulmonary fibrosis drugs market by mechanism of action:
• Antifibrotics
• Tyrosine Kinase Inhibitors
• Anti-inflammatory Drugs
• Immunosuppressants
• Other MoA

This report will have a series of economic case scenarios as to the impact of COVID-19 on the IPF Global market.

• This report also breaks down the revenue forecast for the global anti-idiopathic pulmonary fibrosis drugs market by Innovator and Off-label drugs:
• Innovator Drugs
• Off-label Drugs

• This report provides individual revenue forecasts to 2029 for these national markets:
• US
• Japan
• EU5: Germany, France, the UK, Italy, Spain
• Rest of World

• This report provides individual revenue forecasts to 2029 for these marketed drugs:
• Esbriet
• Ofev

• Our study gives qualitative analysis of the anti-idiopathic pulmonary fibrosis drugs market. It discusses:
• Diagnosed Prevalence of Idiopathic Pulmonary Fibrosis in the G7 markets
• Epidemiology of Idiopathic Pulmonary Fibrosis by disease severity
• Epidemiology of Idiopathic Pulmonary Fibrosis by gender
• Discussion on novel clinical molecules under development for the treatment of Idiopathic Pulmonary Fibrosis
• Pricing and Reimbursement Overview on Ofev and Esbriet (by NICE, SMC, PBAC, CADTH, G-BA, HAS)
• A SWOT Analysis of the anti-idiopathic pulmonary fibrosis drugs market

• Our study discusses the marketed anti-idiopathic pulmonary fibrosis drugs and pipeline anti-idiopathic pulmonary fibrosis drugs from these companies:
• Actelion
• Afferent Pharmaceuticals
• Asahi Kasei Pharma
• Bellerophon Therapeutics
• Biogen
• Boehringer Ingelheim
• FibroGen
• Galapagos
• Galecto Biotech
• Genentech
• Global Blood Therapeutics
• GSK
• Kadmon Pharmaceuticals
• LTT Bio-Pharma
• MediciNova
• Merck
• Moerae
• Pacific Therapeutics
• Promedior
• ProMetic Life Sciences
• Roche
• Sanofi
• Teva
• Zai Lab

Visiongain’s study is intended for anyone requiring commercial analyses for the global Anti-Idiopathic Pulmonary Fibrosis Drugs Market. You find data, trends and predictions.

To access the data contained in this document please email contactus@visiongain.com

Buy our report today Anti-Idiopathic Pulmonary Fibrosis Drugs Market Report 2021-2031: Antifibrotics, Tyrosine Kinase Inhibitors, Anti-inflammatory Drugs, Immunosuppressants, Other MoA, Innovator Drugs. Avoid missing out by staying informed – order our report now.

Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6

Do you have any custom requirements we can help you with? Any need for a specific country, geo region, market segment or specific company information? Contact us today, we can discuss your needs and see how we can help: sara.peerun@visiongain.com

Download sample pages

Complete the form below to download your free sample pages for Anti-Idiopathic Pulmonary Fibrosis Drugs Market Report 2021-2031


Download sample pages

Complete the form below to download your free sample pages for Anti-Idiopathic Pulmonary Fibrosis Drugs Market Report 2021-2031


Latest Pharma news

Visiongain Publishes Food for Special Medical Purpose (FSMP) Market Report 2020-2030

The food for special medical purpose (FSMP) market growth can be attributed to the growing prevalence of metabolic diseases, growing consumer unhealthy lifestyle, and surge in demand from emerging economies such as Asia Pacific, Middle East & Africa, Latin America, and others.

12 April 2021

READ

Visiongain Publishes Cell-Based Assays Market Report to 2030

Growing incidence of chronic diseases; increasing R&D investment for drug discovery research and Growing Adoption of High-Throughput Screening Methodologies are some of the major factors that propel the market growth.

09 April 2021

READ

Visiongain Publishes Cancer Biologics Therapies Market Report 2021-2031

The main drivers for the growth include technological advancements in the development of novel biomarkers, rising preference for minimally or less invasive surgeries, increasing cancer awareness leading to growth in cancer cases, and growing disposable income in emerging economies.

06 April 2021

READ

Visiongain Publishes Artificial Intelligence (AI) in Drug Discovery Market Report 2021-2031

Factors such as increasing data volumes for analysis, quick turnaround time for the discovery and development new drug, computing power, AI also helps in targeted manufacturing and others drive the market growth.

01 April 2021

READ

Categories